Evidence map›Paper›PMID 26770041›Full record

Trial reportJournal of Korean medical science2016

Reappraisal of the Immunogenicity and Safety of Three Hepatitis A Vaccines in Adolescents.

Seo Hee Yoon, Han Wool Kim, Jong Gyun Ahn, In Tae Kim, Jong-Hyun Kim, Kyoung Ae Kong, Kyung-Hyo Kim

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Korean medical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00483470 (Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00483470 phase3completednot on this map

Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose

TypeinterventionalSponsorSanofi Pasteur, a Sanofi CompanyRan2007 to 2008Enrolled720ConditionsHepatitis AArmsHepatitis A vaccine AVAXIM 80U, Hepatitis A vaccine (HAVRIX 720)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Seo Hee YoonDepartment of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Korea.; Center for Vaccine Evaluation and Study, Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, Korea.ORCID 0000-0002-8361-9815
Han Wool KimDepartment of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Korea.; Center for Vaccine Evaluation and Study, Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, Korea.ORCID 0000-0003-3463-3060
Jong Gyun AhnDepartment of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Korea.; Center for Vaccine Evaluation and Study, Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, Korea.ORCID 0000-0001-5748-0015
In Tae KimSeegene Medical Foundation, Seoul, Korea.ORCID 0000-0002-2322-3018
Jong-Hyun KimDepartment of Pediatrics, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.ORCID 0000-0001-8641-7904
Kyoung Ae KongEwha Womans University Mokdong Hospital, Seoul, Korea.ORCID 0000-0003-1658-3282
Kyung-Hyo KimDepartment of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Korea.; Center for Vaccine Evaluation and Study, Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, Korea.ORCID 0000-0002-0333-6808
Ewha Womans University · KRThe Catholic University of Korea St. Vincent's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the overall incidence of hepatitis A in Korea has been decreasing, adolescents remain highly vulnerable to its outbreaks. This study was conducted to compare the immunogenicity and safety of three hepatitis A vaccines in Korean adolescents. Healthy anti-hepatitis A virus seronegative subjects aged 13 to 19 yr were randomized in three equal groups to receive two doses of Avaxim™, Epaxal®, or Havrix®, 6 to 12 months apart. Seroconversion rates one month after the first dose were 98%, 95%, and 93% for Avaxim™, Epaxal®, and Havrix®, respectively. Seroconversion rates reached 100% for all vaccine groups one month after the second dose. Anti-HAV geometric mean concentrations (GMCs) were 7,207.7 mIU/mL (95% CI, 6023.1-8684.7), 1,750.5 mIU/mL (95% CI, 1362.9-2248.3), and 1,953.5 mIU/mL (95% CI, 1459.4-2614.7) after two doses of Avaxim™, Epaxal®, and Havrix® respectively. Avaxim™ was significantly more immunogenic than Epaxal® and Havrix®, whereas there were no significant differences in antibody responses between Epaxal® and Havrix®. Local and systemic solicited adverse events (AEs) were mostly of mild-to-moderate intensity and resolved within 5 days. No serious AEs were reported. In conclusion, all three vaccines are highly immunogenic and well-tolerated in Korean adolescents. (Clinical Trial Registry NCT00483470).

Indexed as

AdolescentAntibody FormationFemaleHepatitis AHepatitis A AntibodiesHepatitis A VaccinesHumansMaleRepublic of KoreaVaccines, InactivatedYoung AdultHepatitis A AntibodiesHepatitis A VaccinesVaccines, InactivatedAdolescentAntibody FormationHepatitis A VaccinesSafety

Identifiers

PMID26770041
PMCPMC4712583
OpenAlexW2224115151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.